Introduction: Gynecological conditions, such as endometriosis and polycystic ovary syndrome (PCOS), are prevalent among women and extend beyond their reproductive implications. There is a potential connection between these conditions and respiratory health, prompting a need for a comprehensive understanding. The pharmacological interventions used to manage gynecological conditions may influence respiratory outcomes, highlighting the intricate interplay between reproductive health and lung function. Objective: The primary objective of this study is to investigate the respiratory implications associated with prevalent gynecological conditions and various pharmacological interventions. Methodology: A prospective cohort study spanning 1.5 years was conducted, involving 150 participants recruited from a tertiary care hospital's respiratory clinic. Inclusion criteria encompassed a diagnosis of endometriosis or PCOS and asthma or chronic obstructive pulmonary disease (COPD), while exclusion criteria included pregnancy, active smoking, or significant respiratory comorbidities. Data, including demographics, diagnoses, medication history, respiratory function tests, symptom scores, and healthcare utilization, were collected from electronic medical records. Statistical analyses, performed using SPSS, involved descriptive statistics, t-tests, ANOVA, and Pearson correlation. Results: Among 145 women predominantly aged 42.5 years, endometriosis (56.7%) and PCOS (43.3%) were prevalent, with asthma (60%) and COPD (40%) as common chest diseases. Pharmacological interventions varied, with oral contraceptives (33.3%) leading. Participants on oral contraceptives exhibited a significant increase in FEV1 (2.5%), while exacerbation rates were lowest with oral contraceptives (1.2/year) and highest with "other" medications (1.7/year). Respiratory symptom scores were highest in the "other" group (18.3). Correlations indicated potential dose-dependent effects of GnRH agonists on FEV1 (-0.35) and a positive correlation between BMI and chest disease exacerbation rate (0.28). Conclusion: The study reveals nuanced respiratory impacts associated with specific gynecological conditions and pharmacological interventions, emphasizing the need for further exploration. The findings underscore the complexity of the relationship between reproductive health and respiratory outcomes, calling for personalized treatment approaches in this population.